Table 3. Treatment and outcome of patients.
| Patient No | Gender | Age (years) | Treatment | Cycle | Outcome | PFS (months) | OS (months) | HSCT |
|---|---|---|---|---|---|---|---|---|
| 1 | F | 3 | mSMILE L-DEP | 2 | PR | 15 | 36 | Y + allo-HSCT |
| 2 | F | 4 | mSMILE | 6 | CR | 37 | 37 | N |
| 3 | M | 5 | mSMILE | 6 | CR | 36 | 36 | Y + auto-HSCT |
| 4 | M | 6 | mSMILE | 6 | CR | 29 | 29 | N |
| 5 | F | 2.5 | mSMILE | 6 | CR | 19 | 19 | N |
| 6 | M | 9.5 | mSMILE L-DEP | 2 | PD | 4 | 4 | Y + allo-HSCT |
| 7 | F | 12 | mSMILE, P-GEMOX | 2 | PR | 59 | 59 | N |
| 8 | F | 3 | SMILE | 6 | CR | 54 | 54 | Y + auto-HSCT |
PFS, progression-free survival; OS, overall survival; HSCT, hematopoietic stem cell transplantation; F, female; mSMILE, modified steroid, methotrexate, ifosfamide, L-asparaginase, and etoposide; L-DEP, pegaspargase + liposomal doxorubicin + etoposide + methylprednisolone; PR, partial remission; Y, received; allo-HSCT, allogeneic HSCT; CR, complete remission; PD, progressive disease; N, not received; M, male; P-GEMOX, pegaspargase + gemcitabine + oxaliplatin.